Adverse effects following COVID-19 vaccination in Iran
- PMID: 35585518
- PMCID: PMC9116064
- DOI: 10.1186/s12879-022-07411-5
Adverse effects following COVID-19 vaccination in Iran
Abstract
Background: Vaccination is a key intervention to prevent COVID-19. Many vaccines are administered globally, yet there is not much evidence regarding their safety and adverse effects. Iran also faces this challenge, especially as data regarding the Sputnik V vaccine is sparse. Therefore, the aim of this study is to determine the adverse effects of the most commonly used vaccines in Iran.
Methods: Using a retrospective cohort study design, 6600 subjects aged 18 years or older who had received two doses of any of the three COVID-19 vaccines (Sinopharm, AstraZeneca, and Sputnik V) were selected using a random sampling method between March and August 2021. Subjects were asked about any adverse effects of the vaccines by trained interviewers via telephone interview. Vaccine-related adverse effects in individuals during the first 72 h and subsequently following both doses of the vaccines were determined. The demographic variables, type of administered vaccine, adverse effects, and history of the previous infection with COVID-19 were collected. Descriptive statistics (mean, standard deviation) and analytical statistics (Chi-squared and Wilcoxon tests) were performed at a 95% significance level using STATA software version 15 (STATA Corp, College Station, TX, USA).
Results: From 6600 participants, 4775 responded (response rate = 72.3%). Of the participants, 1460 (30.6%) received the AstraZeneca vaccine, 1564 (32.8%) received the Sinopharm vaccine and 1751 (36.7%) received the Sputnik V vaccine. 2653 participants (55.56%) reported adverse effects after the first dose and 1704 (35.7%) after the second dose. Sputnik V caused the most adverse effects with 1449 (82.7%) vaccine recipients reporting symptoms after the first or second dose, compared with 1030 (70.5%) for AstraZeneca and only 585 (37.4%) for the Sinopharm vaccine. The most common adverse effects after the first dose were fatigue (28.37%), chill/fever (26.86%), and skeletal pain (22.38%). These three adverse effects were the same for the second dose, although their prevalence was lower.
Conclusions: In this study, we demonstrate that the Sputnik V vaccine has the highest rate of adverse effects, followed by the AstraZeneca and Sinopharm vaccines. COVID-19 vaccines used in Iran are safe and there were no reports of serious adverse effects.
Keywords: Adverse effect; AstraZeneca; COVID-19; Iran; Sinopharm; Sputnik V; Vaccine.
© 2022. The Author(s).
Conflict of interest statement
The authors declare that they have no conflict of interest. The authors alone are responsible for the content and writing of the article.
Similar articles
-
A prospective cohort study protocol: monitoring and surveillance of adverse events following heterologous booster doses of Oxford AstraZeneca COVID-19 vaccine in previous recipients of two doses of Sinopharm or Sputnik V vaccines in Iran.BMC Public Health. 2023 Jul 24;23(1):1415. doi: 10.1186/s12889-023-16265-8. BMC Public Health. 2023. PMID: 37488541 Free PMC article.
-
Reactogenicity within the first week after Sinopharm, Sputnik V, AZD1222, and COVIran Barekat vaccines: findings from the Iranian active vaccine surveillance system.BMC Infect Dis. 2023 Mar 10;23(1):150. doi: 10.1186/s12879-023-08103-4. BMC Infect Dis. 2023. PMID: 36899326 Free PMC article.
-
Side effects of Sputnik V, Oxford-AstraZeneca, Sinopharm, and Covaxin and their associations with other variables among healthcare workers of a tertiary hospital in Iran.Int Immunopharmacol. 2023 Apr;117:109784. doi: 10.1016/j.intimp.2023.109784. Epub 2023 Feb 20. Int Immunopharmacol. 2023. PMID: 36812676 Free PMC article.
-
COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877. Eur Rev Med Pharmacol Sci. 2021. PMID: 33629336 Review.
-
A systematic review of cases of CNS demyelination following COVID-19 vaccination.J Neuroimmunol. 2022 Jan 15;362:577765. doi: 10.1016/j.jneuroim.2021.577765. Epub 2021 Nov 9. J Neuroimmunol. 2022. PMID: 34839149 Free PMC article.
Cited by
-
Side effects associated with homogenous and heterogenous doses of Oxford-AstraZeneca vaccine among adults in Bangladesh: an observational study.Sci Rep. 2024 Oct 11;14(1):23794. doi: 10.1038/s41598-024-75833-z. Sci Rep. 2024. PMID: 39394252 Free PMC article.
-
Side effects after COVID-19 vaccination: a comparison between the most common available vaccines in Iran.Iran J Microbiol. 2023 Apr;15(2):189-195. doi: 10.18502/ijm.v15i2.12467. Iran J Microbiol. 2023. PMID: 37193234 Free PMC article.
-
Evaluation of short-term adverse events of COVID-19 vaccines: An observational study.Medicine (Baltimore). 2024 Feb 23;103(8):e35549. doi: 10.1097/MD.0000000000035549. Medicine (Baltimore). 2024. PMID: 38394514 Free PMC article.
-
The effectiveness of COVID-19 vaccination in preventing hospitalisation and mortality: A nationwide cross-sectional study in Iran.J Glob Health. 2024 Sep 27;14:05026. doi: 10.7189/jogh.14.05026. J Glob Health. 2024. PMID: 39325919 Free PMC article.
-
Surveillance of COVID-19 vaccines: A comprehensive analysis of the first immunization drive in Ecuador.Heliyon. 2024 Mar 8;10(6):e27464. doi: 10.1016/j.heliyon.2024.e27464. eCollection 2024 Mar 30. Heliyon. 2024. PMID: 38509901 Free PMC article.
References
-
- COVID-19 pandemic and comparative health policy learning in Iran IRAN. 2021. https://en.tums.ac.ir/m8-alliance/en/news/156/covid-19-in-iran. - PubMed
-
- Organization WH. Iran (Islamic Republic of), WHO (COVID-19) dashboard: WHO; 2021. https://covid19.who.int/region/emro/country/ir.
-
- Coronavirus second wave, third wave and beyond: what causes a COVID surge. 2021. https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavir....
-
- Fischer WA, Eron JJ, Holman W, Cohen MS, Fang L, Szewczyk LJ, et al. Molnupiravir, an oral antiviral treatment for COVID-19. medRxiv. 2021. 10.1101/2021.06.17.21258639.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical